The Aethlon hemopurifier has been designated a "breakthrough device" by the U.S. FDA related to the treatment of life-threatening viruses not addressed with approved therapies. The proposed research entails an ex vivo evaluation of the medical device as a strategy for the capture and removal of exosomes from the plasma of patients with breast cancer.